Ten post jest także dostępny w języku: polski
The U.S. pharmaceutical company Pfizer announced in a statement that the first test of COVID-19 vaccine developed in cooperation with the German biotechnology company BioNTech has been completed. Currently, there are four types of Pfizer vaccine for Sars-Cov-2 in the testing phase. One of them will be commercially available.
World: ongoing work on COVID-19 vaccine
According to the latest WHO information, as of 2 July 2020, nearly 140 potential candidates for the coronavirus vaccine causing COVID-19 disease are currently being developed. 18 of them are in clinical evaluation.
It is worth noting that according to the WHO information from the end of June 2020, the leading project in this area – and the most advanced one at the same time – is the preparation developed by the British pharmaceutical company AstraZeneca. The work of American company Moderna, about which we wrote more in mid-March, is also promising.
Results of tests on 45 people with Pfizer and BioNTech vaccine
Pfizer and BioNTech conducted the first stage of research on a group of 45 healthy people. They were divided into groups. Nine individuals received a placebo, the others were divided according to the dose administered: 10 mqg, 30 mqg and 100 mqg.
The results of the tests after administration of the vaccine indicated the presence of COVID-19 antibodies. It turns out that their level was about 2-3 times higher than in people who have undergone Sars-Cov-2 disease. Patients who were given two smaller doses at an interval of 21 days had more antibodies than those who received a single, highest dose. The results of recent clinical trials have not yet passed the safety and efficacy assessment.